Home
  • Networks
    • Small molecules
    • Cancer
    • Tissues
    • Cell lines
  • Analysis
    • Drug repurposing (CLUEreg)
    • Enrichment analysis
    • Upload your network
    • Network comparison
    • CCLE map
    • Help
    • GitHub
    • API
    • Changelog
    • Download
    • Contact
    • Changelog
    v0.1 cell line networks
    v0.2 aggregate tissue networks
    v0.3 TF enrichement tool
    v0.4 single-sample tissue networks
    v0.5 CLUEreg tool
    v0.6 colon cancer networks
    v0.7 drug networks
    v0.7.1 API v1
    v0.8 liver, cervix, and breast cancer networks
    v0.9 miRNA tissue networks
    v0.9.1 bootstrap 5
    v1.0 glioblastoma networks
    v1.0.1 drug combinations
    v1.1 Cell line networks
    v1.2 User upload network
    v1.2.1 Gene targeting table
    v1.2.2 DRAGON miRNA network
    v1.3 Network comparison
    v1.3.1 Guided tours
    v1.4.0 CCLE multi-omic map
    v1.5.0 EGRET networks
    v1.6.0 BONOBO networks
    v1.7.0 tcga-data-nf networks

    UVM cancer networks

    Data sets 1 Networks Aggregate 1

    Hover over the bar plot to get the GO term. Differentially targeted genes and TFs were computed by comparing a cancer network to all other cancers.

    Tool description

    PANDA reconstructs a gene regulatory network using TF PPI, TF DNA binding motif, and gene expression samples. You can check the phenotypic information for the clinical variables of the samples that were used to reconstruct the network.
    The variable Samples indicates the number of samples used for network reconstruction. For single-sample networks, clicking the number of samples links to the phenotypic variable table and the individual networks. The number in the Sample variable and the phenotypic variable table may be different because the table can include samples from other studies. For example, in colon cancer, 444 TCGA samples were used to build LIONESS networks in a first study and 445 samples were used for a more recent study. The superset of both TCGA samples is comprised of 487 samples, which is the size of the pheotypic variables table. This discrepancy is due to different pre-processinng techniques, inclusion/exclusion criteria, and sample quality-control.

    Publication
    Please check the reference at the following link.
    # Tissue Tool netZoo release Network
    		 PPI
    		 Motif Expression Regulator nReg Genes Data Samples Precision
    		 Reference
    1 Uveal Melanoma PANDA netZooR 0.9
    AdjCodeVis
    		 TF 644 29375 TCGA 80 D

    Variable description

    This is a description of the primary clinical variables of the gene expression samples that were used to generate the gene regulatory network.

    Sample
    		 Gender Race Stage
    		 Vital status Age
    		 Days to last follow up Tumor ID
    TCGA-V4-A9EF-01A MALE WHITE Stage IIIB Alive 56 719 UVM
    TCGA-YZ-A983-01A FEMALE WHITE Stage IIB Alive 51 154 UVM
    TCGA-V4-A9EK-01A FEMALE WHITE Stage IIB Alive 37 567 UVM
    TCGA-VD-AA8N-01A MALE [Not Evaluated] Stage IIB Alive 86 44 UVM
    TCGA-V4-A9EI-01A MALE WHITE Stage IIIB Dead 78 [Not Available] UVM
    TCGA-VD-A8KL-01A FEMALE [Not Evaluated] Stage IIB Alive 77 3 UVM
    TCGA-VD-A8KM-01A MALE [Not Evaluated] Stage IIB Alive 65 4 UVM
    TCGA-V4-A9EA-01A MALE WHITE Stage IIIA Alive 66 751 UVM
    TCGA-V4-A9E5-01A FEMALE WHITE Stage IIIB Alive 51 1906 UVM
    TCGA-WC-A885-01A MALE WHITE Stage IIA Alive 60 315 UVM
    TCGA-VD-AA8O-01A MALE [Not Evaluated] Stage IIB Alive 77 228 UVM
    TCGA-VD-A8K8-01A FEMALE [Not Evaluated] Stage IIB Alive 56 20 UVM
    TCGA-YZ-A982-01A FEMALE WHITE Stage IIIB Alive 79 159 UVM
    TCGA-VD-A8KK-01A MALE [Not Evaluated] Stage IIIA Alive 54 3 UVM
    TCGA-V4-A9EE-01A MALE WHITE Stage IIB Dead 86 [Not Available] UVM
    TCGA-V4-A9E7-01A MALE WHITE Stage IIIA Dead 76 [Not Available] UVM
    TCGA-V4-A9EY-01A FEMALE WHITE Stage IIIA Alive 66 405 UVM
    TCGA-WC-A883-01A FEMALE WHITE Stage IIIA Dead 76 [Not Available] UVM
    TCGA-V4-A9EQ-01A MALE WHITE Stage IIIA Dead 64 [Not Available] UVM
    TCGA-V3-A9ZY-01A MALE WHITE Stage IIB Alive 54 123 UVM
    TCGA-VD-A8KA-01B MALE [Not Evaluated] Stage IIB Alive 22 842 UVM
    TCGA-V4-A9EU-01A FEMALE WHITE Stage IIIC Alive 83 709 UVM
    TCGA-V4-A9EM-01A MALE WHITE Stage IIIA Alive 53 488 UVM
    TCGA-VD-A8KI-01A MALE [Not Evaluated] Stage IIB Alive 68 38 UVM
    TCGA-V4-A9EL-01A MALE WHITE Stage IIIA Alive 60 583 UVM
    TCGA-V4-A9F2-01A FEMALE WHITE Stage IIIA Alive 78 371 UVM
    TCGA-V3-A9ZX-01A MALE WHITE Stage IIB Alive 56 137 UVM
    TCGA-V4-A9F8-01A MALE WHITE Stage IIIA Alive 68 582 UVM
    TCGA-V4-A9EH-01A MALE WHITE Stage IIIB Alive 53 670 UVM
    TCGA-V4-A9F0-01A MALE WHITE Stage IIIB Alive 59 607 UVM
    TCGA-V4-A9F3-01A FEMALE WHITE Stage IIIA Alive 49 525 UVM
    TCGA-VD-AA8M-01A MALE [Not Evaluated] Stage IIA Alive 64 6 UVM
    TCGA-WC-A88A-01A MALE WHITE Stage IV Dead 75 [Not Available] UVM
    TCGA-VD-A8KF-01A MALE [Not Evaluated] Stage IIIB Dead 68 [Not Available] UVM
    TCGA-VD-AA8S-01B MALE [Not Evaluated] Stage IIA Alive 40 245 UVM
    TCGA-WC-A87W-01A FEMALE WHITE Stage IIA Alive 57 977 UVM
    TCGA-V4-A9E9-01A MALE WHITE Stage IIIA Alive 50 767 UVM
    TCGA-VD-A8KB-01A FEMALE [Not Evaluated] Stage IIB Alive 66 660 UVM
    TCGA-WC-A888-01A MALE WHITE Stage IIB Alive 76 52 UVM
    TCGA-V4-A9F5-01A FEMALE WHITE Stage IV Alive 85 202 UVM
    TCGA-VD-A8K9-01A FEMALE [Not Evaluated] Stage IIA Alive 71 14 UVM
    TCGA-V4-A9ES-01A FEMALE WHITE Stage IIIA Alive 54 1027 UVM
    TCGA-WC-A87Y-01A MALE WHITE [Not Available] Alive 59 369 UVM
    TCGA-VD-AA8P-01A FEMALE [Not Evaluated] Stage IIB Alive 64 86 UVM
    TCGA-V4-A9EV-01A FEMALE WHITE Stage IIIA Alive 59 836 UVM
    TCGA-YZ-A985-01A FEMALE WHITE Stage IIIA Alive 41 599 UVM
    TCGA-V4-A9ET-01A MALE WHITE Stage IIIB Alive 57 872 UVM
    TCGA-VD-A8KD-01A MALE [Not Evaluated] Stage IV Dead 72 [Not Available] UVM
    TCGA-VD-A8KJ-01A MALE [Not Evaluated] Stage IIB Alive 53 961 UVM
    TCGA-V4-A9EO-01A MALE WHITE Stage IIIA Alive 74 407 UVM
    TCGA-V4-A9F4-01A MALE WHITE Stage IIIA Alive 41 256 UVM
    TCGA-VD-AA8R-01A FEMALE [Not Evaluated] Stage IIB Alive 78 2 UVM
    TCGA-V4-A9F7-01A FEMALE WHITE Stage IIB Alive 78 927 UVM
    TCGA-WC-A881-01A MALE WHITE Stage IIB Alive 75 694 UVM
    TCGA-WC-A882-01A FEMALE WHITE Stage IIB Alive 50 344 UVM
    TCGA-WC-A880-01A MALE WHITE Stage IIIA Alive 63 842 UVM
    TCGA-WC-A87T-01A MALE WHITE Stage IIB Alive 64 2149 UVM
    TCGA-WC-AA9E-01A MALE WHITE Stage IIA Alive 60 315 UVM
    TCGA-VD-A8KG-01A FEMALE [Not Evaluated] Stage IIA Alive 47 19 UVM
    TCGA-WC-AA9A-01A FEMALE WHITE Stage IIA Dead 70 [Not Available] UVM
    TCGA-YZ-A980-01A MALE WHITE Stage IIIA Alive 75 1283 UVM
    TCGA-VD-A8KN-01A FEMALE [Not Evaluated] Stage IIA Alive 60 7 UVM
    TCGA-VD-A8KO-01A MALE [Not Evaluated] Stage IIA Alive 51 26 UVM
    TCGA-VD-A8KH-01A MALE [Not Evaluated] Stage IIIB Alive 69 10 UVM
    TCGA-V4-A9EW-01A FEMALE WHITE Stage IIIA Alive 44 774 UVM
    TCGA-RZ-AB0B-01A FEMALE WHITE Stage IV Dead 47 [Not Available] UVM
    TCGA-VD-A8KE-01A FEMALE [Not Evaluated] Stage IIA Alive 74 6 UVM
    TCGA-V4-A9F1-01A FEMALE WHITE Stage IIB Alive 46 556 UVM
    TCGA-V4-A9EX-01A FEMALE WHITE Stage IIIA Dead 55 [Not Available] UVM
    TCGA-YZ-A984-01A FEMALE WHITE Stage IIB Alive 50 946 UVM
    TCGA-VD-AA8T-01A FEMALE [Not Evaluated] Stage IIA Alive 83 49 UVM
    TCGA-V4-A9EJ-01A MALE WHITE Stage IIB Alive 38 382 UVM
    TCGA-VD-AA8Q-01A MALE [Not Evaluated] Stage IIB Alive 71 2 UVM
    TCGA-V4-A9EC-01A FEMALE WHITE Stage IIB Alive 75 743 UVM
    TCGA-VD-A8K7-01B MALE [Not Evaluated] Stage IIIA Alive 39 3 UVM
    TCGA-V4-A9EZ-01A FEMALE WHITE Stage IIB Alive 78 599 UVM
    TCGA-V4-A9E8-01A MALE WHITE Stage IIIA Dead 49 [Not Available] UVM
    TCGA-V4-A9ED-01A MALE WHITE Stage IIIA Alive 45 654 UVM
    TCGA-WC-A87U-01A MALE WHITE Stage IIIA Dead 73 [Not Available] UVM
    TCGA-WC-A884-01A FEMALE WHITE Stage IIIB Alive 35 12 UVM
    Sample Gender Race Stage Status Age Days to follow up Tumor ID
    Contact

    Department of Biostatistics
    Harvard T.H. Chan School of Public Health

    License
    Share